Endevica Bio

About Endevica Bio

Endevica Bio is dedicated to pioneering science-driven solutions in peptide therapeutics, aiming to transform patient outcomes in cancer cachexia and metabolic disorders with innovative therapies that overcome limitations of existing treatments.

Products & Services

TCMCB07 (Cancer Cachexia Drug):A drug for cancer cachexia, currently in a Phase 2 trial starting in 2025, aimed at redefining the standard of care in oncology.

710GO (Weight Loss Drug):A weight loss drug for obesity, showing an 11.7% weight reduction in obese non-human primates over 15 weeks without GLP-1-like side effects.

Specialties

Peptide Therapeutics Cancer Cachexia Metabolic Disorders Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2023-01-19 FD: 2023-01-19	1 investors

Series B Latest

2023-01-19

$10.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Russell Potterfield

Chief Executive Officer

LinkedIn (Pro only)

D

Daniel Marks

Chief Scientific and Medical Officer

LinkedIn (Pro only)

Recent News

Endevica Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised